CapEval Pharma provides advice and guidance aimed at addressing regulatory challenges encountered during the drug development process.
We help our customers manage the risks associated with product development evaluating both the scientific and regulatory issues that will impact their programs and we develop strategies for a successful regulatory submission.
Regulatory due diligence can be undertaken for in- and out- licensing opportunities.
We can evaluate reports and documentation for regulatory compliance in the area of chemistry, manufacturing and analytical controls and provide an expert review including for example: key questions, gaps in manufacturing and controls, assessment of regulatory risk and strategy.
Our approach to the drug development process means we are well equipped to respond to questions raised by regulatory agencies.
We can interact with regulatory agency personnel to ensure agency and sponsor understanding of CMC, regulatory and non-clinical development data.
A strong regulatory strategy relies on identifying phase appropriate requirements to ensure the quality, safety, and efficacy of the drug.
Appropriate controls have to be identified and implemented before, during and after production and testing acceptance criterion have to be met.
Documentation must be traceable, legible, accurate and detailed and include conclusive analyses and results.
To ensure success in this area, we can work with you at the start of product development or manage the process in its entirety, from supply of clinical trial material onwards.
CapEval Pharma
218 Av. Marie Curie, 74160 Archamps France